Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review

References

• Forman D, CJ L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30:F12–F23.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, et al. Human papillomavirus and related diseases report HPV center 2019 Accessed 12 January 2021. Available from: https://www.hpvcentre.net/statistics/reports/XWX.pdf
   Google Scholar
• Castellsagué X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108(6):6.
   Google Scholar
• World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020.
   Google Scholar
• de Sanjose S, Brotons M, LaMontagne DS, et al. Human papillomavirus vaccine disease impact beyond expectations. Curr Opin Virol. 2019;39:16–22.
   PubMed Web of Science ®Google Scholar
• Wu T, Hu Y-M, Li J, et al. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: a randomized controlled phase 2 clinical trial. Vaccine. 2015;33(32):3940–3946.
   PubMed Web of Science ®Google Scholar
• de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670.
   PubMed Web of Science ®Google Scholar
• Serrano B, Brotons M, Bosch FX, et al. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstetrics Gynaecol. 2018;47:14–26.
   PubMed Web of Science ®Google Scholar
• Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814.
   PubMed Web of Science ®Google Scholar
• Pou AM, Rimell FL, Jordan JA, et al. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. SAGE Publications Sage Los Angeles; 1995.
   Google Scholar
• Bruni L, Saura-Lazaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144:106399.
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard E, Perez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization coverage 2020 Accessed 12 January 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
   Google Scholar
• Vanska S, Luostarinen T, Baussano I, et al. Vaccination with moderate coverage eradicates oncogenic human papillomaviruses if a gender-neutral strategy is applied. J Infect Dis. 2020 Aug 17;222(6):948–956.
   PubMed Web of Science ®Google Scholar
• Lehtinen M, Soderlund-Strand A, Vanska S, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949–958.
   PubMed Web of Science ®Google Scholar
• World Health Organization. One-dose human papillomavirus (HPV) vaccine offers solid protection against cervical cancer 2022 Accessed 30 April 2022. Available from: https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer
   Google Scholar
• Center for Vaccine Innovation and Access. Single-Dose HPV Vaccine Evaluation Consortium 2022 Accessed 17 April 2022 [updated April 2022]. Available from: https://www.path.org/programs/center-for-vaccine-innovation-and-access/single-dose-hpv-vaccine-evaluation-consortium/
   Google Scholar
• Schiller JT, Lowy DR. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32):4768–4773.
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard E, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015 May;15(5):565–580.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper. Vaccine. 2017;35(43):5753–5755.
   PubMed Web of Science ®Google Scholar
• Johnson Jones ML, Gargano JW, Powell M, et al. Effectiveness of 1, 2, and 3 doses of human papillomavirus vaccine against high-grade cervical lesions positive for human papillomavirus 16 or 18. Am J Epidemiol. 2020 Apr 2;189(4):265–276.
   PubMed Web of Science ®Google Scholar
• Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012 Dec 1;206(11):1645–1651.
   PubMed Web of Science ®Google Scholar
• Harper DM, DeMars LR. HPV vaccines – a review of the first decade. Gynecol Oncol. 2017;146(1):196–204.
   PubMed Web of Science ®Google Scholar
• Ramondetta L. Response to Harper and De Mars, HPV vaccines: a review of the first decade. Gynecol Oncol Rep. 2017 Nov;22:113–114.
   PubMedGoogle Scholar
• Hariri S, Schuler MS, Naleway AL, et al. Human papillomavirus vaccine effectiveness against incident genital warts among female health-plan enrollees, United States. American Journal of Epidemiology. 2018;187(2):298–305.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfstrom KM, et al. HPV Vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020 Oct 1;383(14):1340–1348.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-world effectiveness of human papillomavirus vaccination against cervical cancer. Journal of the National Cancer Institute: JNCI; 2021.
   Google Scholar
• Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016 Aug 15;63(4):519–527.
   PubMed Web of Science ®Google Scholar
• Brown DR, Joura EA, Yen GP, et al. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine. 2021;39(16):2224–2236.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccine efficacy, effectiveness and protection 2021 Accessed 19 July 2022. Available from: https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection
   Google Scholar
• Hanquet G, Valenciano M, Simondon F, et al. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013 Nov 19;31(48):5634–5642.
   PubMed Web of Science ®Google Scholar
• Oxford Vaccine Group. Herd immunity (Herd protection): University of Oxford. Accessed 21 March 2022]. Available from: https://vk.ovg.ox.ac.uk/vk/herd-immunity
   Google Scholar
• Enerly E, Flingtorp R, Christiansen IK, et al. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway. PLoS One. 2019;14(10):e0223612.
   PubMed Web of Science ®Google Scholar
• Goggin P, Sauvageau C, Gilca V, et al. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada. Hum Vaccin Immunother. 2018;14(1):118–123.
   PubMed Web of Science ®Google Scholar
• Heard I, Tondeur L, Arowas L, et al. Effectiveness of human papillomavirus vaccination on prevalence of vaccine genotypes in young sexually active women in France. J Infect Dis. 2017;215(5):757–763.
   PubMed Web of Science ®Google Scholar
• Berenson AB, Hirth JM, Chang M. Change in human papillomavirus prevalence among U.S. Women Aged 18-59 Years, 2009-2014. Obstet Gynecol. 2017 2017-1-1;130(4):693–701.
   PubMed Web of Science ®Google Scholar
• Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-national health and nutrition examination survey, United States, 2003-2014. J Infect Dis. 2017;216(5):594–603.
   PubMed Web of Science ®Google Scholar
• Tarney CM, Klaric J, Beltran T, et al. Prevalence of Human Papillomavirus in Self-Collected Cervicovaginal Swabs in Young Women in the United States Between 2003 and 2012. Obstet Gynecol. 2016;128(6):1241–1247.
   PubMed Web of Science ®Google Scholar
• Dillner J, Nygård M, Munk C, et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018 Jun 18;36(26):3820–3829.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination. J Infect Dis. 2018;217(10):1590–1600.
   PubMed Web of Science ®Google Scholar
• Feiring B, Laake I, Christiansen IK, et al. Substantial decline in prevalence of vaccine-type and nonvaccine-type human papillomavirus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV Vaccine in Norway. J Infect Dis. 2018 Nov 5;218(12):1900–1910.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Widdice LE, Ding L, et al. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clin Infect Dis. 2016;63(10):1281–1287.
   PubMed Web of Science ®Google Scholar
• McGregor S, Saulo D, Brotherton JML, et al. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: the VIP-I study. Vaccine. 2018 Jul 5;36(29):4311–4316.
   PubMed Web of Science ®Google Scholar
• Jacot-Guillarmod M, Pasquier J, Greub G, et al. Impact of HPV vaccination with Gardasil(R) in Switzerland. BMC Infect Dis. 2017;17(1):790.
   PubMedGoogle Scholar
• Hirth J, McGrath CJ, Kuo YF, et al. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S. Vaccine. 2018 Nov 29;36(50):7682–7688.
   PubMed Web of Science ®Google Scholar
• Hirth JM, Kuo YF, Starkey JM, et al. Regional variations in human papillomavirus prevalence across time in NHANES (2003-2014). Vaccine. 2019 Jul 9;37(30):4040–4046.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Chow EP, Garland SM, et al. Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis. 2017;215(2):202–208.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Naleway AL, Lewis RM, et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: evidence of direct and herd effects of vaccination. Vaccine. 2019 Jun 27;37(29):3918–3924.
   PubMed Web of Science ®Google Scholar
• Sarr EHM, Mayrand MH, Coutlee F, et al. Exploration of the effect of human papillomavirus (HPV) vaccination in a cohort of pregnant women in Montreal, 2010-2016. Heliyon. 2019 Aug;5(8):e02150.
   PubMed Web of Science ®Google Scholar
• Saccucci M, Ding L, et al. Non-vaccine-type human papillomavirus prevalence after vaccine introduction: no evidence for type replacement but evidence for cross-protection. Sex Transm Dis. 2018;45(4):260–265.
   PubMed Web of Science ®Google Scholar
• Covert C, Ding L, Brown D, et al. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. Hum Vaccin Immunother. 2019 Jan;11:1–8.
   Google Scholar
• Garland SM, Cornall AM, Brotherton JML, et al. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine. 2018 May 31;36(23):3221–3230.
   PubMed Web of Science ®Google Scholar
• Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis. 20172017-1-1;17(1):68–77.
   PubMed Web of Science ®Google Scholar
• Gargano JW, Unger ER, Liu G, et al. Prevalence of genital human papillomavirus in males, United States, 2013-2014. J Infect Dis. 2017;215(7):1070–1079.
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin oncol. 2018;36(3):262–267.
   PubMed Web of Science ®Google Scholar
• Han JJ, Beltran TH, Song JW, et al. Prevalence of genital human papillomavirus infection and human papillomavirus vaccination rates among us adult men: national health and nutrition examination survey (NHANES) 2013-2014. JAMA Oncol. 2017;3(6):810–816.
   PubMed Web of Science ®Google Scholar
• Chow EPF, Tabrizi SN, Fairley CK, et al. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017. Vaccine. 2019 Oct 31;37(46):6907–6914.
   PubMed Web of Science ®Google Scholar
• Widdice LE, Bernstein DI, Franco EL, et al. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. Vaccine. 2019 Oct 23;37(45):6832–6841.
   PubMed Web of Science ®Google Scholar
• Ali H, McManus H, O’Connor CC, et al. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Med J Aust. 2017;206(5):204–209.
   PubMed Web of Science ®Google Scholar
• Cocchio S, Baldovin T, Bertoncello C, et al. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 2017;17(1):249.
   PubMedGoogle Scholar
• Flagg EW, Torrone EA. Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014. Am J Public Health. 2018;108(1):112–119.
   PubMed Web of Science ®Google Scholar
• Lurie S, Mizrachi Y, Chodick G, et al. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure. Gynecol Oncol. 2017;146(2):299–304.
   PubMed Web of Science ®Google Scholar
• Steben M, Tan Thompson M, Rodier C, et al. A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J Obstet Gynaecol Can. 2018 Dec;40(12):1635–1645.
   PubMed Web of Science ®Google Scholar
• Checchi M, Mesher D, Mohammed H, et al. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017. Sex Transm Infect. 2019 Aug;95(5):368–373.
   PubMed Web of Science ®Google Scholar
• Orumaa M, Kjaer SK, Dehlendorff C, et al. The impact of HPV multi-cohort vaccination: real-world evidence of faster control of HPV-related morbidity. Vaccine. 2020 Feb 5;38(6):1345–1351.
   PubMed Web of Science ®Google Scholar
• Herweijer E, Ploner A, Sparen P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine. 2018;36(15):1917–1920.
   PubMed Web of Science ®Google Scholar
• Thone K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC Infect Dis. 2017;17(1):564.
   PubMedGoogle Scholar
• Silverberg MJ, Leyden WA, Lam JO, et al. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. Lancet Child Adolesc Health. 2018 Oct;2(10):707–714.
   PubMedGoogle Scholar
• Ozawa N, Ito K, Tase T, et al. Beneficial effects of human papillomavirus vaccine for prevention of cervical abnormalities in Miyagi, Japan. Tohoku J Exp Med. 2016;240(2):147–151.
   PubMed Web of Science ®Google Scholar
• Ozawa N, Ito K, Tase T, et al. Lower incidence of cervical intraepithelial neoplasia among young women with human papillomavirus vaccination in Miyagi, Japan. Tohoku J Exp Med. 2017;243(4):329–334.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shirasawa H, Shimizu D, et al. Preventive effect of human papillomavirus vaccination on the development of uterine cervical lesions in young Japanese women. J Obstet Gynaecol Res. 2017;43(10):1597–1601.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yaegashi N, Iwata T, et al. Early impact of the Japanese immunization program implemented before the HPV vaccination crisis. Int J Cancer. 2017;141(8):1704–1706.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Yagi A, Nakayama T, et al. Dynamic changes in Japan’s prevalence of abnormal findings in cervical cervical cytology depending on birth year. Sci Rep. 2018 Apr 4;8(1):5612.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Yaegashi N, Iwata T, et al. Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program. Cancer Sci. 2019 Dec;110(12):3811–3820.
   PubMed Web of Science ®Google Scholar
• Karube A, Saito F, Nakamura E, et al. Reduction in HPV 16/18 prevalence among young women following HPV vaccine introduction in a highly vaccinated district, Japan, 2008-2017. J Rural Med. 2019 May;14(1):48–57.
   PubMedGoogle Scholar
• Brotherton JM, Budd A, Rompotis C, et al. Is one dose of human papillomavirus vaccine as effective as three?: a national cohort analysis. Papillomavirus Res. 2019 Dec;8:100177.
   PubMed Web of Science ®Google Scholar
• Brotherton JM, Gertig DM, May C, et al. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016 Mar 21;204(5):184–184e1.
   PubMed Web of Science ®Google Scholar
• Cleveland AA, Gargano JW, Park IU, et al. Cervical adenocarcinoma in situ: human papillomavirus types and incidence trends in five states, 2008-2015. Int J Cancer. 2020 Feb 1;146(3):810–818.
   PubMed Web of Science ®Google Scholar
• Robertson G, Robson SJ. Excisional Treatment of Cervical Dysplasia in Australia 2004-2013: a Population-Based Study. J Oncol. 2016;2016:3056407.
   PubMed Web of Science ®Google Scholar
• Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3(6):833–837.
   PubMed Web of Science ®Google Scholar
• Kim J, Bell C, Sun M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. Cmaj. 2016;188(12):E281–8.
   PubMed Web of Science ®Google Scholar
• Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: a Danish nationwide cohort study. Clin Infect Dis. 2020 Feb 3;70(4):608–614.
   PubMed Web of Science ®Google Scholar
• Dehlendorff C, Sparén P, Baldur-Felskov B, et al. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions. Vaccine. 2018 Oct 15;36(43):6373–6378.
   PubMed Web of Science ®Google Scholar
• Racey CS, Albert A, Donken R, et al. cervical intraepithelial neoplasia rates in british columbia women: a population-level data linkage evaluation of the school-based HPV immunization program. J Infect Dis. 2020 Jan 1;221(1):81–90.
   PubMed Web of Science ®Google Scholar
• Hofstetter AM, Ompad DC, Stockwell MS, et al. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr. 2016;170(5):445–452.
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Diaz A, Shankar V, et al. Risk of delayed human papillomavirus vaccination in inner-city adolescent women. J Infect Dis. 2016;214(12):1952–1960.
   PubMed Web of Science ®Google Scholar
• Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study. Cancer. 2020 Apr 15;126(8):1656–1667.
   PubMed Web of Science ®Google Scholar
• Chandler E, Ding L, Gorbach P, et al. Epidemiology of any and vaccine-type anogenital human papillomavirus among 13-26-year-old young men after HPV vaccine introduction. J Adolesc Health. 2018 Jul;63(1):43–49
   PubMed Web of Science ®Google Scholar
• Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012 Apr;54(7):891–898.
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Burk RD, Nucci-Sack A, et al. Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations. PLoS One. 2012;7(5):e37419.
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Masika M, Diaz A, et al. Risk of oral human papillomavirus infection among sexually active female adolescents receiving the quadrivalent vaccine. JAMA Network Open. 2019 Oct 2;2(10):e1914031.
   PubMed Web of Science ®Google Scholar
• Kahn JA, Rudy BJ, Xu J, et al. Behavioral, immunologic, and virologic correlates of oral human papillomavirus infection in HIV-infected youth. Sex Transm Dis. 2015;42(5):246–252.
   PubMed Web of Science ®Google Scholar
• Grün N, Ährlund-Richter A, Franzén J, et al. Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in Sweden, a follow up-study 2013-2014 after gradual introduction of public HPV vaccination. Infect Dis (Lond). 2015 Jan;47(1):57–61.
   PubMed Web of Science ®Google Scholar
• Brouwer AF, Eisenberg MC, Carey TE, et al. Multisite HPV infections in the United States (NHANES 2003-2014): an overview and synthesis. Prev Med. 2019 Jun;123:288–298.
   PubMed Web of Science ®Google Scholar
• Hirth JM, Chang M, Resto VA. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30years old). Vaccine. 2017 Jun 14;35(27):3446–3451.
   PubMed Web of Science ®Google Scholar
• Novakovic D, Cheng ATL, Zurynski Y, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018 Jan 4;217(2):208–212.
   PubMed Web of Science ®Google Scholar
• Gallagher KE, Erio T, Baisley K, et al. The impact of a human papillomavirus (HPV) vaccination campaign on routine primary health service provision and health workers in Tanzania: a controlled before and after study. BMC Health Serv Res. 2018 Mar 12;18(1):173.
   PubMedGoogle Scholar
• Rosenblum HG, Lewis RM, Gargano JM, et al. Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine — United States, 2003–2018. MMWR Morb Mortal Wkly Rep. 2021;70:415–420.
   PubMed Web of Science ®Google Scholar
• Chow EP, Tabrizi SN, Fairley CK. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. Lancet Infect Dis. 2021;21;10:1448–1457.
   PubMed Web of Science ®Google Scholar
• Steben M, Thompson MT, Rodier C, et al. A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J Obstet Gynaecology Canada. 2018;40(12):1635–1645.
   PubMed Web of Science ®Google Scholar
• Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health. 2018;108(1):112–119.
   PubMed Web of Science ®Google Scholar
• Orumaa M, Kjaer SK, Dehlendorff C, et al. The impact of HPV multi-cohort vaccination: real-world evidence of faster control of HPV-related morbidity. Vaccine. 2020;38(6):1345–1351.
   PubMed Web of Science ®Google Scholar
• Organization WH. Closing immunization gaps caused by COVID-19 2020 Accessed 21 March 2022. Available from: https://cdn.who.int/media/docs/default-source/immunization/catch-up/closing-immunization-gaps-caused-by-covid-19-v11.pdf?sfvrsn=8a91a2bd_2
   Google Scholar
• de Sanjose S, Is BL. It now the time to plan for global gender-neutral HPV vaccination? J Infect Dis. 2020 Aug 17;222(6):888–889.
   PubMed Web of Science ®Google Scholar
• Garland SM, Stanley MA, Giuliano AR, et al. IPVS statement on ”Temporary HPV vaccine shortage: implications globally to achieve equity”. Papillomavirus Res. 2020 Jun;9:100195.
   PubMed Web of Science ®Google Scholar
• Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:106399.
   PubMed Web of Science ®Google Scholar
• Enerly E, Berger S, Kjær SK, et al. Use of real-world data for HPV vaccine trial follow-up in the Nordic region. Contemp Clin Trials. 2020 May;92:105996.
   PubMed Web of Science ®Google Scholar
• Guo F, Cofie LE, Berenson AB. Decreasing trends in cervical cancer incidence among young women (15-34 years) in the United States during the human papillomavirus (HPV) Vaccine Era. Cancer Epidemiol Biomarkers Prev. 2017;26(3):3.
   PubMed Web of Science ®Google Scholar
• Guo F, Cofie LE, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med. 2018 Aug;55(2):197–204.
   PubMed Web of Science ®Google Scholar
• Hidalgo-Tenorio C, Pasquau J, Omar-Mohamed M, et al. Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years. Viruses. 2021 Jan 20;13(2):2.
   Web of Science ®Google Scholar
• Dehlendorff C, Baandrup L, Kjaer SK. Real-world effectiveness of Human Papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers. JNCI. 2021;113(7):869–874.
   PubMedGoogle Scholar
• Goldenberg M.Public trust in vaccines. 34th International Papillomavirus Conference; 2021 November
   Google Scholar
• London School of Hygiene and Tropical Medicine. Vaccine Confidence Project Accessed 5 January 2021 . Available from: https://www.vaccineconfidence.org/the-confidence-project
   Google Scholar
• WHO/UNICEF. Estimates of national immunization coverage analytics 2021 Accessed 21 March 2022. Available from: https://data.unicef.org/resources/immunization-coverage-estimates-data-visualization
   Google Scholar
• gov.uk. Off-label vaccines - An introductory guide for healthcare professionals 2019 Accessed 21 March 2022. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/832917/Off_label_cold-chain_healthcare_professionals.pdf
   Google Scholar
• Bornstein J, Roux S, Kjeld Petersen L, et al. Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. Pediatrics. 2021;147(1):1.
   Web of Science ®Google Scholar
• El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: cytology, molecular testing, both or none. J Clin Virol. 2016;76:S62–S68.
   PubMed Web of Science ®Google Scholar
• Hall MT, Simms KT, Lew J-B, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4(1):e19–e27.
   PubMed Web of Science ®Google Scholar
• Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health. 2021 Feb;9(2):e161–e169.
   PubMed Web of Science ®Google Scholar
• Rohner E, Bütikofer L, Schmidlin K, et al. Cervical cancer risk in women living with HIV across four continents: a multicohort study. Int J Cancer. 2020 Feb 1;146(3):601–609.
   PubMed Web of Science ®Google Scholar
• Nishimura H, Yeh PT, Oguntade H, et al. HPV self-sampling for cervical cancer screening: a systematic review of values and preferences. BMJ Glob Health. 2021;6(5):e003743.
   PubMed Web of Science ®Google Scholar
• Nelson EJ, Maynard BR, Loux T, et al. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect. 2017;93(1):56–61.
   PubMed Web of Science ®Google Scholar
• Aarnio R, Isacson I, Sanner K, et al. Comparison of vaginal self‐sampling and cervical sampling by medical professionals for the detection of HPV and CIN2+: a randomized study. Int J Cancer. 2021;148(12):3051–3059.
   PubMed Web of Science ®Google Scholar
• De Pauw H, Donders G, Weyers S, et al. Cervical cancer screening using HPV tests on self-samples: attitudes and preferences of women participating in the VALHUDES study. Arch Public Health. 2021;79(1):1–9.
   PubMed Web of Science ®Google Scholar
• Hashim D, Engesæter B, Baadstrand Skare G, et al. Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. Br J Cancer. 2020;122(11):1715–1723.
   PubMed Web of Science ®Google Scholar
• Machalek DA, Roberts JM, Garland SM, et al. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. Med j Aust. 2019;211(3):113–119.
   PubMed Web of Science ®Google Scholar
• Cook DA, Krajden M, Brentnall AR, et al. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. Int J Cancer. 2019;144(10):2587–2595.
   PubMed Web of Science ®Google Scholar
• Dick S, Kremer WW, De Strooper LM, et al. Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. Gynecol Oncol. 2019;154(2):368–373.
   PubMed Web of Science ®Google Scholar
• Vink F, Lissenberg-Witte BI, Meijer C, et al. FAM19A4/miR124-2 methylation analysis as a triage test for HPV-positive women: cross-sectional and longitudinal data from a Dutch screening cohort. Clin Microbiol Infect. 2021;27(1):125.e1–125.
   PubMed Web of Science ®Google Scholar
• Torres-Ibarra L, Cuzick J, Lorincz AT, et al. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus–based screening in Mexico. JAMA network open. 2019;2(11):e1915781–e1915781.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Rezhake R, Yuill S, et al. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. Br J Cancer. 2020;122:1577–1579.
   PubMed Web of Science ®Google Scholar
• Stoler MH, Baker E, Boyle S, et al. Approaches to triage optimization in HPV primary screening: extended genotyping and p16/Ki‐67 dual‐stained cytology—Retrospective insights from ATHENA. Int J Cancer. 2020;146(9):2599–2607.
   PubMed Web of Science ®Google Scholar
• Smith MA, Sherrah M, Sultana F, et al. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study .BMJ. 2022;376:e068582.
   PubMedGoogle Scholar
• Daniels V, Saxena K, Roberts C, et al. Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: a model based analysis. Vaccine. 2021;39(20):2731–2735.
   PubMed Web of Science ®Google Scholar
• Poljak M, Cuschieri K, Waheed DEN, et al. Impact of the COVID-19 pandemic on human papillomavirus-based testing services to support cervical cancer screening. Acta Dermatovenerol Alp Pannonica Adriat. 2021;30(1):21–26.
   PubMed Web of Science ®Google Scholar